GlassScriptPhysician profile
Vishwanath Pattan
NPI 1770902330
$1,874.24
in general payments reported to CMS, 2019-2025
20 companies · $511 in 2025
The $511 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.74 · 2023: $391 · 2024: $918 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $295.65 | 2019-2025 | Tepezza |
| Recordati_rare_diseases_inc. | $290.35 | 2023-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $181.43 | 2023-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Tandem Diabetes Care, INC. | $172.43 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $158.62 | 2023-2025 | Tymlos |
| Novo Nordisk INC | $154.35 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $129.05 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $105.15 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $94.59 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $62.74 | 2024 | Mounjaro, Zepbound, Jardiance |
| Horizon Therapeutics Plc | $41.84 | 2023 | Tepezza |
| Amneal Pharmaceuticals LLC | $30.95 | 2024 | Unithroid |
| Ibsa Pharma INC. | $23.75 | 2025 | Tirosint, Flector, Licart |
| Pfizer INC. | $22.23 | 2024 | |
| Neurocrine Biosciences, INC. | $20.80 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2025 | Jardiance |
| Abbvie INC. | $19.78 | 2024 | |
| Dexcom, INC. | $19.15 | 2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $16.72 | 2019 | |
| Beta Bionics, INC. | $14.66 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishwanath Pattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.